Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C
- 1 July 1992
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 35 (4), 246-250
- https://doi.org/10.1007/bf01789330
Abstract
On the basis of our clinical findings that the ability of cancer patients to generate lymphokine-activated killer cells became markedly augmented after mitomycin C administration, we designed a treatment regimen comprising mitomycin C 12 mg/m2, i.v. on day 1 and recombinant interleukin-2 700 U/m2 (8000 IU/kg), i.v. every 12 h from day 4 through day 8. The treatment course was repeated at almost 7-day intervals. Altogether 33 patients with advanced carcinoma, including mainly gastrointestinal carcinoma, were treated with this regimen. Of these, 10 had a partial response (PR) and 4 had a minor response (MR). Since eosinophil counts peaked 1 day after either the first or second course of the therapy, the posttreatment values were compared to each pretreatment level, with regard to the clinical antitumor response to this treatment. When patients who showed PR were defined as responders, absolute eosinophil counts and the percentages of eosinophils in responders after both the first and second courses of the therapy were significantly greater than each pretreatment value or the posttreatment level in nonresponders. Further, these findings were almost identical, when both PR and MR were considered to be a true remission and therefore patients who exhibited PR or MR were defined as responders, although the difference between posttreatment levels of eosinophils in responders and nonresponders was not significant at the second course. These results indicate that eosinophilia induced by this treatment correlates with the clinical response to this therapy.Keywords
This publication has 31 references indexed in Scilit:
- Phase II Trial of High-Dose Intermittent Interleukin-2 in Metastatic Renal Cell Carcinoma: A Southwest Oncology Group StudyJNCI Journal of the National Cancer Institute, 1990
- Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humansCancer Immunology, Immunotherapy, 1989
- Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3.JCI Insight, 1988
- Recombinant human interleukin 5 is a selective activator of human eosinophil function.The Journal of Experimental Medicine, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Tumour inhibition by interleukin-2 at the tumour/host interfaceBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1986
- Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival.JCI Insight, 1986
- Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytesBiochemical and Biophysical Research Communications, 1982
- Tumour-associated eosinophilia: a review.Journal of Clinical Pathology, 1981